Affimed NV【AFMD】株式ニュース

個人投資家向けのプロ仕様のツール。

プレミアム

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients

Data update from AFM24-102 Phase 1/2a combination study includes 15 heavily pre-treated patients from the...

Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)

In 32 patients with relapsed/refractory (r/r) Hodgkin lymphoma (HL) treated at the recommended phase 2 dose...

Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24

Review clinical data of acimtamig in combination with cord-blood derived NK cells presented at ASH 2023;...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress

Acimtamig (also known as AFM13) combination with AlloNK® (also known as AB-101): Initiated LuminICE-203...

Affimed Announces Acimtamig as International Nonproprietary Name for AFM13

MANNHEIM, Germany, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the...

Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023

MANNHEIM, Germany, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage...

Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

Addition of Affimed’s innate cell engager (ICE®) improves cytotoxicity of natural killer (NK) cells and CAR-NK...

Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting

In 36 patients with CD30-positive lymphoma treated at the recommended Phase 2 dose level (RP2D), the...

Affimed to Participate in Upcoming Investor Conferences

MANNHEIM, Germany, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Affimed Announces Listing Transfer to Nasdaq Capital Markets

MANNHEIM, Germany, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the...

Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

MANNHEIM, Germany, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the...

Affimed to Present at the Cantor Global Healthcare Conference 2023

MANNHEIM, Germany, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the...

Rendering Error

jondoeuk 3月前

AFM24 is on life support https://www.oncologypipeline.com/apexonco/affimed-needs-more-time-afm24

👍️0

glenn1919 3月前

AFMD..............................https://stockcharts.com/h-sc/ui?s=AFMD&p=W&b=5&g=0&id=p86431144783

03/08/2024 19:50:00 AFMD Affimed N.V. NASDAQ
T1

https://twitter.com/health_stocks/status/1765339556025364562

👍️0

Renee 12月前

AFMD: effective March 11,2024 a one for 10 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php

👍️0

glenn1919 1年前

AFMD......................................https://stockcharts.com/h-sc/ui?s=AFMD&p=W&b=5&g=0&id=p86431144783

👍️0

Invest-in-America 1年前

AFMD: A town in Nevada named after a RACE HORSE!!!??? (LOVE-IT!!!!)

"You better STOP that kind of DANCING, Mister!!! Or I will phone HOMELAND DEFENSE!!!"

👍️0

Triple nickle 1年前

One more good news release and this rockets to 1.35 and better

👍️ 1

befast 1年前

Unfortunately in the wrong direction. If a rather positive presentation causes a 20+% decrease in share price, imagine what would happen with a negative one. You either stay silent or provide better narrative to rest your case. AFMD management should step in if they believe the presentation was not duly understood

ASCO starts today. Looking forward to CC tomorrow at 6pm.

NK is a slow cooker looking at MDACC data. It takes a lot of convincing before it starts killing, unlike CART. None has died on auto and allo NK as many claimed.

👍️0

jondoeuk 2年前

I am worried about the potential for on-target, off-tumour toxicities as the target is expressed by a number of healthy cells, including HSCs.

👍️0

NY1972 2年前

CD123 is found in CSCs, which are not effectively eliminated by chemotherapy, have the capacity to self-renew, and are capable recapitulating disease. Thus, approaches to target are highly sought and have been tested in preclinical and clinical settings.

Why CD123? https://finance.yahoo.com/news/affimed-announces-first-patient-successfully-103000071.html

👍️0

mrplmer 2年前

Really. Not my experience.

👍️0

turning stone 2年前

Everyone have a happy, healthy and prosperous NEW YEAR

GO AFMD!!!!!!!! 2023 is yours for the asking

👍️0

turning stone 2年前

Okay it is time for more shareholders to get on this board and rally for a major up swing. All the signs show an upswing is here.

👍️0

turning stone 2年前

There was really NO need for the share price to crash. Even two major analyst agree and moved up the stocks upward value. 65% percent of the open float is owned by institutions who don't seem to have a clue about this company. This is great news for me as I will keep buying more shares as the share price tumbles. I thought the German people were very smart I guess not. We shall see.

Post # 278 below please do not open the PDF file. Someone added some malware to it so DO NOT CLICK ON IT. Sorry that a jerk had to ruin the link.

When is the next event that could move this stock?

👍️0

stockguard 3年前

Equity Research
Company Update — December 2, 2021
Biotechnology A?med NV (AFMD)
AFMD: Virtual NDR Highlights Unique Technology, Pipeline Depth, Breadth and Near-Term Value Drivers

https://www.docdroid.net/A28l2M1/wells-fargo-afmd-research-12-2-21-1-pdf

👍️0

stockguard 3年前

Affimed: A small-cap biotech with room to run
Bucking the downward trend in biopharma in 2021, Affimed, a small-cap cancer immunotherapy company, has seen its shares actually rise by a healthy 19.8% this year. This tiny immunotherapy company has been able to swim against the current this year due to some truly eye-catching clinical trial data.

Last week, Affimed reported that its lead product candidate AFM13, when combined with a dose of natural killer cells, produced a 100% objective response rate in heavily pre-treated patients with recurrent or refractory CD30-positive lymphomas. AFM13 is thus on track to become the go-to therapy for later-line CD30-positive lymphomas; an indication that ought to be worth around $500 million to $600 million in sales per year.

To put these extremely preliminary revenue figures into context, Affimed currently sports a market cap of just $834 million. That's the key reason why Wall Street thinks this stock could more than double in value over the next 12 months.

Despite its relatively strong year, Affimed's novel anti-cancer platform still comes off as grossly undervalued at these levels. The company could eventually generate billions in sales and it stands out as a top buyout target right now.
https://www.fool.com/investing/2021/11/28/3-best-biopharma-stocks-to-buy-during-this-industr/

👍️0

mrplmer 3年前

Buyout coming soon. Pòtential 10B market.

👍️0

stockguard 3年前

Affimed stock jumps 22% after reporting 100% ORR in Phase 1-2 lymphoma study
Nov. 22, 2021 7:43 AM ETAffimed N.V. (AFMD)By: Mamta Mayani
Affimed (NASDAQ:AFMD) soars 21.6% premarket after announcing interim clinical results from Phase 1-2 study, evaluating cord blood-derived natural killer (cbNK) cells pre-complexed with Affimed’s innate cell engager (ICE) AFM13.
As of October 31, 2021, a total of 18 patients with CD30-positive relapsed or refractory Hodgkin and non-Hodgkin lymphomas (16 and 2 patients, respectively) were treated with the novel combination of cbNK cells pre-complexed with AFM13.
As of the cutoff date, 16 of 18 patients had achieved an objective response to the treatment according to investigator assessment, with seven complete responses (CR) and nine partial responses.
100% objective response rate (ORR) was observed with a 42% CR rate in 12 patients with Hodgkin Lymphoma, after the 1st of 2 planned cycles at the recommended phase 2 dose of 108 cbNK cells/kg pre-complexed with AFM13.
No cases of serious adverse events such as cytokine release syndrome, neurotoxicity syndrome or graft-versus-host disease were observed.
Treatment was well tolerated with five reported cases of transient infusion related reactions after the monotherapy infusions of AFM13.

https://seekingalpha.com/news/3773189-affimed-stock-jumps-18-after-reporting-100-orr-in-phase-1-2-lymphoma-study

Lol What do you call the day before yesterday

Below post on conference was canceled.
Members, Thank you very much for your interest. Our sincere apologies but the doctor has a patient emergency, and we will need to reschedule this call. We will keep you posted. Thank you, Slingshot Insights

👍️0

stockguard 3年前

This one could be interesting for a novice and also the informed, plus it states "AFMD CALL IS FREE FOR ALL" and you are able to add questions before the call. I joined the call that will be in about 2 hours Pacific time-01:00 PM PDT-AFMD-Understanding the potential of AFM13 + NK Cells in CD30-positive lymphomas. Interview Goal
This conversation will discuss the current standard of care for lymphoma patients and the potential of AFM13. We'll ask how meaningful CRs are for patients who failed multiple lines of prior therapies, durability expectations for responses, and what line AFM13 might fall if successful. Sign up below: https://mailchi.mp/slingshotinsights/4-calls-today-on-si-bvhn-jnj-hospital-rev-cycle-cms-patient-surveys-1990719
mailchi.mp
4 Calls Today on SI: NVS, CRIS, CCXI & AFMD (Free to Join)

👍️0

stockguard 3年前

This morning AFMD Affimed initiated with a Buy at Truist
Truist analyst Srikripa Devarakonda initiated coverage of Affimed with a Buy rating and $10 price target. The analyst cites the company's phase 1 proof of concept data in two rare blood cancers, along with "futility hurdle" that Affirmed passed in pivotal trials, both of which support a peak sales opportunity of about
$500M. Devarakonda further notes the potential near-term upside for Affirmed from updated data from lead drug + NK cell combo likely to be presented at ASH2021.

👍️0

mrplmer 3年前

Anyday now when it goes to $50 I am pretty sure youll be sorry you didnt follow my advise. Nuff said. They arent chasing amyloid plaçque. Sigmar1 receptor hold the key to CNS. Bye bye.

👍️0

stockguard 3年前

mrplmer

Alzheimer's is way to speculative for any company at this stage so I would take a pass on the stock this early on but appreciate the heads up. My father-in-law just was diagnosed with Alzheimer's and I wish there was a biotech play seriously close to some relief for those sufferers and their families.
I follow biotech and invest in the space heavily, so I stay on top of a wide range of bio`s. But Alzheimer's biotech research has not reached that investable point for me yet as there still is too much downside risk in the smaller bio`s research. GLTY with Anavex

👍️0

mrplmer 3年前

If you are not "in" on Anavex then ya better find some powder. They might just have the cure for many CNS diseases. Their Blacarsimine is safe effective and works on Rett syndrome Parkinson's Disease and Dementia. Readouts in the next 2 months. Alzheimer's readout 2nd Q 2022. It agonizes the Sigmar1 receptor and creates cellular homeostasis. IT will be huge. Due Diligence important.

👍️0

stockguard 3年前

From below post:
Affimed: A new way to engage the immune system
Cancer immunotherapy has revolutionized the way oncologists approach the treatment of numerous liquid and solid tumors. Even so, the first generation of checkpoint inhibitors and genetically modified cellular therapies is far from 100% effective. Some of these novel treatments also come with a host of serious and potentially life-threatening side effects that limit their use in certain patient populations.

Affimed, a small-cap immunotherapy company, is trying to change this narrative by engaging the body's own immune system with a platform consisting of so-called "bi-specific antibodies" that active natural killer cells to attack tumor cells.

While the early stage results of the company's lead candidate, known as AFM13, have been impressive as a monotherapy from both an efficacy and safety standpoint, Affimed is also evaluating this therapy in combination with cord blood-derived natural killer cells, as well as checkpoint inhibitors. Wall Street, for its part, thinks this single biologic therapy could rake in well over $600 million at its peak.

Where do things stand now? Affimed is hoping to file its first regulatory application for AFM13 as a monotherapy indicated for patients with relapsed/refractory peripheral T-cell lymphoma. If things go according to plan, the biotech's first therapy could be on the market by perhaps 2023. Before then, however, there is a strong possibility that Affimed simply gets bought out. Big pharma has been on the hunt of late for early-stage cancer immunotherapy companies with unique assets, and Affimed fits that mold to a tee.

All told, Affimed's shares appear to be a downright steal at these levels. The company's market cap of $707 million arguably doesn't properly represent the promise of its anticancer platform -- even on a risk-adjusted basis. Affimed, after all, has already presented strong early stage results for its novel immunotherapy platform. Another major clinical update is reportedly slated to happen at a medical conference in the fourth-quarter of this year, according to the company's last quaterly update. Aggressive investors, therefore, might be wise to consider buying this undervalued biotech stock soon.
https://www.fool.com/investing/2021/10/18/2-biotech-stocks-poised-to-go-supernova-soon/

👍️0

stockguard 3年前

2 Biotech Stocks Set to Go Supernova Soon
https://www.fool.com/investing/2021/10/18/2-biotech-stocks-poised-to-go-supernova-soon/

👍️0

stockguard 4年前

Affimed (NASDAQ:AFMD) Receives $13.75 Average PT from Brokerages
Posted by Max Byerly on Jul 26th, 2021
Affimed (NASDAQ:AFMD) has been given an average rating of “Buy” by the six ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $13.75.
https://www.tickerreport.com/banking-finance/7687643/affimed-nasdaqafmd-receives-13-75-average-pt-from-brokerages.html

👍️0

stockguard 4年前

Advancing Immuno-Oncology by believing in the potential of the immune system to restore patients’ innate ability to fight cancer

https://www.rdworldonline.com/advancing-immuno-oncology-by-believing-in-the-potential-to-restore-patients-ability-to-fight-cancer/

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Affimed NV (AFMD)

個人投資家向けのプロ仕様のツール。

AFMD ニュース

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients

Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)

Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress

Affimed Announces Acimtamig as International Nonproprietary Name for AFM13

Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023

Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting

Affimed to Participate in Upcoming Investor Conferences

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Affimed Announces Listing Transfer to Nasdaq Capital Markets

Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

Affimed to Present at the Cantor Global Healthcare Conference 2023

AFMD 財務

AFMD Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Affimed NV (AFMD) ニュース

Affimed NV (AFMD)

個人投資家向けのプロ仕様のツール。

AFMD ニュース

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients

Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)

Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress

Affimed Announces Acimtamig as International Nonproprietary Name for AFM13

Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023

Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting

Affimed to Participate in Upcoming Investor Conferences

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Affimed Announces Listing Transfer to Nasdaq Capital Markets

Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

Affimed to Present at the Cantor Global Healthcare Conference 2023

AFMD 財務

AFMD Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

広告を削除する